New chemo cocktail targets rare small bowel tumors

NCT ID NCT06835387

Recruiting now Disease control Sponsor: Tiago Biachi de Castria Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 29, 2026 · Updated 2 times

Summary

This phase 2 trial tests a four-drug chemotherapy combination called NALIRIFOX in 36 adults with advanced small bowel adenocarcinoma that cannot be removed by surgery. The drugs are given intravenously on days 1 and 15 of each 28-day cycle for up to 6 cycles, followed by a milder maintenance treatment. The main goal is to see how many patients' tumors shrink or disappear.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NALIRIFOX (nanoliposomal irinotecan, oxaliplatin, fluorouracil, and folinic acid)
What this could lead to: If successful, this could provide a new treatment option to shrink or control advanced small bowel tumors that cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial with only 36 participants, so results may not apply to everyone. Chemotherapy side effects like nausea, nerve damage, and low blood counts are expected risks.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SMALL BOWEL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

small intestine adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SMALL BOWEL ADENOCARCINOMA

Contacts and locations

Locations

Atlantic Health System
RECRUITING

Morristown, New Jersey, 07960, United States
Moffitt Cancer Center
RECRUITING

Tampa, Florida, 33612, United States
Parkview Research Center
RECRUITING

Fort Wayne, Indiana, 46845, United States
University of Illinois Cancer Center
RECRUITING

Chicago, Illinois, 60612, United States
University of Texas Southwestern Medical Center
RECRUITING

Dallas, Texas, 75390, United States
Virginia Commonwealth University
RECRUITING

Richmond, Virginia, 23298, United States
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.